Mar 27, 2023 / 12:00PM GMT
Operator
Good morning and welcome to the UNITY Biotechnology conference call and webcast. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the UNITY website following the conclusion of the event.
I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of UNITY Biotechnology. Please go ahead, Lynn.
Lynne Sullivan - Unity Biotechnology, Inc. - CFO, Head of Corporate Development
Thanks, Tara. Good morning, and thank you for joining UNITY Biotechnology's conference call to review the 24-week data from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet AMD.
With me on today's call is Anirvan Ghosh, the CEO of UNITY Biotechnology; Jamie Dananberg, our Chief Medical Officer; myself, Lynne Sullivan, the Chief Financial Officer; and we are fortunate to have Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates, joining us for today's webcast.
Before turning the call over to Anirvan, I'd like to remind you that
UNITY Biotechnology Inc To Discuss Phase 2 ENVISION Program Update Call Transcript
Mar 27, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers